Stock Price
109.14
Daily Change
-6.48 -5.60%
Monthly
-23.57%
Yearly
60.22%
Q2 Forecast
106.95

Insmed reported $704.85M in Equity Capital and Reserves for its fiscal quarter ending in March of 2026.





Equity Capital And Reserves Change Date
BioMarin Pharmaceutical USD 6.21B 125.11M Mar/2026
Cytokinetics USD -826.57M 166.94M Mar/2026
DBV Technologies USD 168.77M 115.92M Dec/2025
Gilead Sciences USD 23.52B 897M Mar/2026
Heron Therapeutics USD 9.14M 4.15M Mar/2026
Insmed USD 704.85M 34.12M Mar/2026
Novartis USD 46.13B 1.8B Dec/2025
Regeneron Pharmaceuticals USD 31.42B 166.7M Mar/2026
Sarepta Therapeutics USD 1.51B 364.48M Mar/2026
Ultragenyx Pharmaceutical USD -236M 156M Mar/2026
Vertex Pharmaceuticals USD 19.36B 696.1M Mar/2026